Skip to main content

Novo Nordisk partners with Sempre Health

partnership (Getty Images)

With a mission to lower healthcare costs, Sempre Health has partnered with Novo Nordisk in a pilot programme.

The duo will add diabetes medications to the Sempre Health affordability and engagement solution. Unlike traditional coupons and vouchers, Sempre works with health plans to reward their membership's positive choices and actions once their goals are reached.

"We are excited to combine Sempre's nuanced approach to affordability and adherence with Novo Nordisk's innovative portfolio of medications," commented Anurati Mathur, CEO of Sempre Health.

"Savings are seamlessly applied to patients' co-pays wherever they normally fill their prescriptions."

The two companies are seeking to engage 10,000 patients with diabetes on the Sempre Health platform in 2018.

See also

Taking medication as prescribed, particularly diabetes medication, is tied to better clinical outcomes and reduced healthcare costs. With Sempre's text messaging-based programs and partnerships with national pharmacies, patients can finally share in the savings they generate for the system by simply following their treatment regimen.

Rich DeNunzio, Vice President of market access strategy and innovation, explained: "The platform that Sempre developed is one, in our mind, that is dynamic because it alters the benefit design, reducing the out-of-pocket cost for patients, while at the same time increasing adherence to drive down total cost of care,” he said.

“Sempre works with health plans to opt in to its system, and pharma company partners add their treatments to the program. It's working with other pharma companies along with Novo Nordisk”, added Sempre CEO Anurati Mathur.

"This is the first of several innovations we plan to pilot to help reduce how much patients pay for their diabetes medicines at the pharmacy. And because consistently taking medicines is important for blood sugar control, we're keen to see Sempre Health's adherence approach support patients," noted Steve Albers, Corporate Vice President, Market Access and Public Affairs, Novo Nordisk Inc.